375 related articles for article (PubMed ID: 30259416)
1. Emerging ways to treat breast cancer: will promises be met?
Samadi P; Saki S; Dermani FK; Pourjafar M; Saidijam M
Cell Oncol (Dordr); 2018 Dec; 41(6):605-621. PubMed ID: 30259416
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
3. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Dey N; De P; Leyland-Jones B
Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
[TBL] [Abstract][Full Text] [Related]
4. Resistance to Targeted Therapies in Breast Cancer.
Braga S
Methods Mol Biol; 2016; 1395():105-36. PubMed ID: 26910072
[TBL] [Abstract][Full Text] [Related]
5. Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood-brain barrier and treatment strategies.
Chhichholiya Y; Ruthuparna M; Velagaleti H; Munshi A
Clin Transl Oncol; 2023 May; 25(5):1218-1241. PubMed ID: 36897508
[TBL] [Abstract][Full Text] [Related]
6. New Immunotherapy Strategies in Breast Cancer.
Yu LY; Tang J; Zhang CM; Zeng WJ; Yan H; Li MP; Chen XP
Int J Environ Res Public Health; 2017 Jan; 14(1):. PubMed ID: 28085094
[TBL] [Abstract][Full Text] [Related]
7. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
[TBL] [Abstract][Full Text] [Related]
8. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
9. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Bashari MH; Fan F; Vallet S; Sattler M; Arn M; Luckner-Minden C; Schulze-Bergkamen H; Zörnig I; Marme F; Schneeweiss A; Cardone MH; Opferman JT; Jäger D; Podar K
Breast Cancer Res; 2016 Feb; 18(1):26. PubMed ID: 26921175
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer.
Lv Q; Meng Z; Yu Y; Jiang F; Guan D; Liang C; Zhou J; Lu A; Zhang G
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983617
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
12. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
13. Anti-breast-Cancer Activity Exerted by β-Sitosterol-d-glucoside from Sweet Potato via Upregulation of MicroRNA-10a and via the PI3K-Akt Signaling Pathway.
Xu H; Li Y; Han B; Li Z; Wang B; Jiang P; Zhang J; Ma W; Zhou D; Li X; Ye X
J Agric Food Chem; 2018 Sep; 66(37):9704-9718. PubMed ID: 30160115
[TBL] [Abstract][Full Text] [Related]
14. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
15. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.
Johnston SR
Int J Gynecol Cancer; 2006; 16 Suppl 2():543-8. PubMed ID: 17010069
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
17. Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research.
Aquino-Jarquin G
Cancer Res; 2017 Dec; 77(24):6812-6817. PubMed ID: 29208606
[TBL] [Abstract][Full Text] [Related]
18. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
19. The clinical development of vaccines for HER2
Costa RLB; Soliman H; Czerniecki BJ
Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
[TBL] [Abstract][Full Text] [Related]
20. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
